Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Cope, Shannon
    • Other Affiliation: MAPI Consultancy, Toronto, Canada
  • Donohue, James F
    • Affiliation: School of Medicine, Department of Medicine
  • Jansen, Jeroen P
    • Other Affiliation: MAPI Consultancy, Boston, USA
  • Kraemer, Matthias
    • Other Affiliation: Novartis Pharma AG, Basel, Switzerland
  • Capkun-Niggli, Gorana
    • Other Affiliation: Novartis Pharma AG, Basel, Switzerland
  • Baldwin, Michael
    • Other Affiliation: Novartis Horsham Research Centre, Horsham, UK
  • Buckley, Felicity
    • Other Affiliation: MAPI Consultancy, Boston, USA
  • Ellis, Alexandra
    • Other Affiliation: MAPI Consultancy, Boston, USA
  • Jones, Paul
    • Other Affiliation: Division of Clinical Science, St George’s University of London, London, UK
Abstract
  • Abstract Background Clinicians are faced with an increasingly difficult choice regarding the optimal bronchodilator for patients with chronic obstructive pulmonary disease (COPD) given the number of new treatments. The objective of this study is to evaluate the comparative efficacy of indacaterol 75/150/300 μg once daily (OD), glycopyrronium bromide 50 μg OD, tiotropium bromide 18 μg/5 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID, and placebo for moderate to severe COPD. Methods Forty randomized controlled trials were combined in a Bayesian network meta-analysis. Outcomes of interest were trough and post-dose forced expiratory volume in 1 second (FEV1), St. George’s Respiratory Questionnaire (SGRQ) score and responders (≥4 points), and Transition Dyspnea Index (TDI) score and responders (≥1 point) at 6 months. Results Indacaterol was associated with a higher trough FEV1 than other active treatments (difference for indacaterol 150 μg and 300 μg versus placebo: 152 mL (95% credible interval (CrI): 126, 179); 160 mL (95% CrI: 133, 187)) and the greatest improvement in SGRQ score (difference for indacaterol 150 μg and 300 μg versus placebo: -3.9 (95% CrI -5.2, -2.6); -3.6 (95% CrI -4.8, -2.3)). Glycopyrronium and tiotropium 18 μg resulted in the next best estimates for both outcomes with minor differences (difference for glycopyrronium versus tiotropium for trough FEV1 and SGRQ: 18 mL (95% CrI: -16, 51); -0.55 (95% CrI: -2.04, 0.92). Conclusion In terms of trough FEV1 and SGRQ score indacaterol, glycopyrronium, and tiotropium are expected to be the most effective bronchodilators.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Cope et al.; licensee BioMed Central Ltd.
Language
  • English
Bibliographic citation
  • Respiratory Research. 2013 Oct 07;14(1):100
Publisher
  • BioMed Central

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 12931_2013_article_1423.pdf 2019-05-07 Public Download
file details 12931_2013_1423_moesm6_esm.pdf 2019-05-07 Public Download
file details 12931_2013_1423_moesm4_esm.pdf 2019-05-07 Public Download
file details 12931_2013_1423_moesm2_esm.pdf 2019-05-07 Public Download
file details 12931_2013_1423_moesm7_esm.pdf 2019-05-07 Public Download
file details 12931_2013_1423_moesm1_esm.doc 2019-05-07 Public Download
file details 12931_2013_1423_moesm3_esm.pdf 2019-05-07 Public Download
file details 12931_2013_1423_moesm5_esm.pdf 2019-05-07 Public Download
file details 12931_2013_1423_moesm8_esm.pdf 2019-05-07 Public Download